Indeterminate cell histiocytosis (ICH) is a rare and controversial disorder first described by Wood et al 1 in 1985. ICH is characterized by a nonepidermotropic histiocytic infiltrate with immunohistochemical features that overlap with Langerhans cells (LCs) and nonLCs of monocyte-macrophage-dendritic cell lineage.
xanthogranuloma, and 1 case of Rosai-Dorfman disease), all of which were negative. FISH studies were performed with positive and negative metaphase controls demonstrating appropriate results. All cases expressed CD68 by IHC and showed a histiocyte-predominate infiltrate histopathologically. All cases of LCH were reactive for langerin and CD1a, whereas all cases that were neither ICH nor LCH were negative for these markers. Three of 5 LCH cases tested with BRAF V600E IHC were positive, as is consistent with the literature. 5 The Rosai-Dorfman disease case expressed S100 by IHC and demonstrated emperipolesis by conventional microscopy. The juvenile xanthogranuloma cases were S100 negative and included Touton-type multinucleated cells.
Herein, we present 3 cases of ICH with an ETV3-NCOA2 translocation, which appears absent in other histiocytic disorders, most importantly LCH. Furthermore, the case of LCH with an increased population of indeterminate cells fails to demonstrate this translocation, indicating that ICH may represent a clonal disorder that is distinct from reactive populations of indeterminate cells. LCH is understood to represent a clonal proliferation of LCs, with recent studies demonstrating alterations in the RAS-RAF-MEK pathway, most notably a BRAF V600E mutation in 50% to 60% of patients. 5 In contrast, strong support for ICH clonality has not been presented to date. NCOA2 encodes nuclear receptor coactivator 2, a transcription factor required for homeostatic balance between white and brown adipose tissue.
6 ETV3 encodes Ets variant 3, a transcriptional repressor involved in macrophage growth arrest via inhibition of Ras-dependent proliferation. 7 Translocations involving NCOA2 have been observed in mesenchymal chondrosarcoma, spindle cell rhabdomyosarcoma, prostate cancer, colon cancer, acute leukemia, and soft tissue angiofibroma, whereas ETV3 abnormalities have been For [6] [7] [8] [9] Neoplastic associations of ICH are limited to case reports that include patients with mast cell leukemia, acute myeloid leukemia, and B-cell lymphoma.
10 Patient 2 had a remote history of breast cancer treated with chemotherapy; however, no patient was noted to have a malignancy at the time of their ICH diagnosis or at 5 and 4 months (patients 1 and 2, respectively) after diagnosis based on available follow-up information. The ETV3-NCOA2 gene fusion presents a potential diagnostic and therapeutic tool for addressing the challenges associated with the controversial and rare entity that is ICH and merits further exploration.
In immunoglobulin light chain (AL) amyloidosis, amyloid fibril deposits, derived from immunoglobulin light chains produced by a clonal plasma cell dyscrasia, accumulate in extracellular tissues and damage vital organs.
1 High-dose melphalan and autologous stem cell transplantation (HDM/SCT) have been shown to induce both hematologic and clinical remissions in selected patients with AL amyloidosis, and it prolongs survival substantially when hematologic remissions are achieved.
We report on the outcome for AL amyloidosis patients treated with HDM/SCT for a .20-year period to address remission durability and long-term results. We previously reported on our experience of 312 patients treated with HDM/SCT in 2004, 2 and this series was updated in Blood in 2011 with 421 patients. 3 The first HDM/SCT for AL amyloidosis was performed in July 1994 at the Amyloidosis Center at Boston University School of Medicine. Patients have been enrolled in several sequential institutional review board-approved protocols during the 20-year study period. Eligibility criteria for all protocols required biopsy proof of amyloid disease; evidence of a plasma cell dyscrasia and exclusion of other types of amyloidosis as appropriate; $1 major affected organ; and adequate measures of cardiac and pulmonary function and performance status. Inclusion criteria included cardiac ejection fraction $40%, absence of symptomatic pleural effusions, absence of uncompensated heart failure or arrhythmias resistant to medical management, oxygen saturation $95% on room air, lung diffusion capacity $50% predicted, supine systolic blood pressure $90 mm Hg, BLOOD, 12 NOVEMBER 2015 x VOLUME 126, NUMBER 20 CORRESPONDENCE 2345
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